UNSPSC 51141575: Ralitoline

This classification denotes an anticonvulsant agent with the molecular formula C13H13ClN2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q4MW9RM93A, chemically known as (z)-6-chloro-3-methyl-4-oxo-delta(sup 2,alpha)-thiazolidineaceto-o-toludide but generally known as ralitoline, which bears US NIH Compound Identifier 6436118. European Medicines Agency schedules Ralitoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10242MIG. The term RALITOLINE is an International Non-Proprietary Name.

UNSPSC 51141575 Ralitoline, a Commodity code, describes pharmaceutical and medical products that state and local governments procure to support public health initiatives, though the recent opportunity record indicates a mismatch between the code's nominal scope and the work actually being solicited. Seminole County, Florida's posted solicitation (IFB 60459723LAS) seeks 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually—opioid-reversal medications and drug disposal equipment rather than Ralitoline itself. The county's procurement is designed to support community health operations with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must submit bids electronically through the county's e-Procurement Portal, include all shipping and delivery costs in pricing, comply with drug-free workplace certification and E-Verify requirements, and maintain workers' compensation, commercial general liability, and professional liability insurance. The contract carries an initial two-year term with an optional one-year renewal and includes a three-month probationary period allowing termination with or without cause. Potential FEMA funding introduces additional federal compliance obligations, including adherence to the Clean Air Act and Federal Water Pollution Control Act.

The code shows minimal recent activity specifically aligned with Ralitoline procurement; the single posted opportunity under this code targets naloxone and drug-deactivation equipment rather than the pharmaceutical indicated by the code's name. Seminole County, a Florida county health department, posted the IFB with a response deadline of July 26, 2023—a date that has now passed—and no subsequent opportunities under this code are present in the current record. The mismatch between code classification and actual procurement scope, combined with the absence of active opportunities, suggests that this code may not be a reliable indicator of current state and local buying activity in its stated category. Business development professionals should verify whether naloxone and drug-deactivation systems are being procured under an alternative UNSPSC code or whether this code itself requires reclassification.